XML 23 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Statements of Changes in Partners' Capital - USD ($)
Limited Partners
Total
Balances at beginning of period at Dec. 31, 2022 [1] $ 429,338,476  
Addition of (-), 17,150,000#, (-) and 63,325,000# partnership shares, respectively [1],[2] 2,141,023,984  
Redemption of (-), (21,100,000)#, (-) and (35,350,000)# partnership shares, respectively [1],[2] (1,114,142,572)  
Net income (loss) (335,900,739) [1] $ (335,900,739)
Balances at end of period at Jun. 30, 2023 [1] 1,120,319,150  
Balances at beginning of period at Mar. 31, 2023 [1] 1,163,415,181  
Addition of (-), 17,150,000#, (-) and 63,325,000# partnership shares, respectively [1],[2] 444,818,165  
Redemption of (-), (21,100,000)#, (-) and (35,350,000)# partnership shares, respectively [1],[2] (598,098,871)  
Net income (loss) 110,184,675 [1] 110,184,675
Balances at end of period at Jun. 30, 2023 [1] 1,120,319,150  
Balances at beginning of period at Dec. 31, 2023 973,854,332 [1] 973,854,332
Addition of (-), 17,150,000#, (-) and 63,325,000# partnership shares, respectively [1],[2] 873,731,717  
Redemption of (-), (21,100,000)#, (-) and (35,350,000)# partnership shares, respectively [1],[2] (1,145,017,798)  
Net income (loss) 9,506,807 [1] 9,506,807
Balances at end of period at Jun. 30, 2024 712,075,058 [1] 712,075,058
Balances at beginning of period at Mar. 31, 2024 [1] 830,500,981  
Addition of (-), 17,150,000#, (-) and 63,325,000# partnership shares, respectively [1],[2] 260,549,798  
Redemption of (-), (21,100,000)#, (-) and (35,350,000)# partnership shares, respectively [1],[2] (553,053,897)  
Net income (loss) 174,078,176 [1] 174,078,176
Balances at end of period at Jun. 30, 2024 $ 712,075,058 [1] $ 712,075,058
[1] General Partners’ shares outstanding and capital for the periods presented were zero.
[2] On January 23, 2024 there was a 1 - for - 4 reverse share split. The Statement of Changes in Partners’ Capital have been adjusted for the periods shown to reflect the 1 - for - 4 reverse share split on a retroactive basis.